APA (7th ed.) Citation

L, B., L, A., M, A., M, G., E, B., G, G., . . . JB, H. (2025). Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial. Annals of oncology : official journal of the European Society for Medical Oncology, 36(7), 796. https://doi.org/10.1016/j.annonc.2025.03.016

Chicago Style (17th ed.) Citation

L, Bergmann, et al. "Prospective Randomized Phase-II Trial of Ipilimumab/nivolumab Versus Standard of Care in Non-clear Cell Renal Cell Cancer - Results of the SUNNIFORECAST Trial." Annals of Oncology : Official Journal of the European Society for Medical Oncology 36, no. 7 (2025): 796. https://doi.org/10.1016/j.annonc.2025.03.016.

MLA (9th ed.) Citation

L, Bergmann, et al. "Prospective Randomized Phase-II Trial of Ipilimumab/nivolumab Versus Standard of Care in Non-clear Cell Renal Cell Cancer - Results of the SUNNIFORECAST Trial." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 36, no. 7, 2025, p. 796, https://doi.org/10.1016/j.annonc.2025.03.016.